Fused heterocyclic compounds as gpr120 agonists

A compound of formula (I);

• wherein,
• X1 is —O—, —S— or —NR′;
• X2 is —O—, —S—, —N—, —NR′—, —CR′— or —CR′R″—;
• Ring A is (C6-C10)aryl or 5- to 10-membered heteroaryl;
• Ring B is (C3-C8)cycloalkyl, (C5-C8)cycloalkenyl, (C6-C10)aryl, 5- to 10-membered heteroaryl or a saturated or partially unsaturated 3- to 11-membered heterocyclyl ring containing one to four heteroatoms independently selected from the group consisting of O, N and S;
• R1 is hydrogen or (C1-C6)alkyl;
• R2 at each occurrence is independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, nitro, —NR5R6, —C(O)R5, —C(O)NR5R6, —S(O)tR7, (C1-C6)alkyl, halo(C1-C6)alkyl, —O(C1-C6)alkyl and (C6-C10)aryl;
• R3 and R4 at each occurrence are independently selected from the group consisting of hydrogen, halogen, oxo, cyano, nitro, —NR5R6, —C(O)R5, —C(O)NR5R6, —S(O)tR7, (C1-C6)alkyl, halo(C1-C6)alkyl, hydroxy, —O(C1-C6)alkyl, (C3-C8)cycloalkyl, (C6-C10)aryl, —O(C6-C10)aryl, heterocyclyl and heteroaryl;
• R5 and R6 are independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C6-C10)aryl, heterocyclyl and heteroaryl;
• R7 is hydrogen, (C1-C6)alkyl or —NR5R6;
• R′ and R″ are independently selected from the group consisting of hydrogen, (C1-C6)alkyl, —C(O)(C1-C6)alkyl, —C(O)O(C1-C6)alkyl and —S(O)2(C1-C6)alkyl;
• or
• R′ and R″ are taken together to form oxo, (C3-C8)cycloalkyl, (C5-C8)cycloalkenyl, or 3- to 6-membered saturated or a partially unsaturated heterocyclyl ring containing one or two heteroatoms independently selected from the group consisting of O, N and S;
• Ra and Rb at each occurrence are independently selected from the group consisting of hydrogen, halogen and (C1-C6)alkyl;
• n is an integer from 1 to 6;
• p is an integer from 1 to 3;
• q is an integer from 1 to 4;
• t is an integer from 0 to 2;
• ------ represents presence or absence of a single bond;
• wherein,
• (C1-C6)alkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, nitro, —NR5R6, —C(O)R5, —C(O)NR5R6, —S(O)tR7, (C1-C6)alkyl, halo(C1-C6)alkyl, —O(C1-C6)alkyl, (C3-C8)cycloalkyl, (C6-C10)aryl, heterocyclyl and heteroaryl;
• wherein R5, R6, R7 and t are as defined above;
• —O(C1-C6)alkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, nitro, —NR5R6, —C(O)R5, —C(O)NR5R6, —S(O)tR7, (C1-C6)alkyl, halo(C1-C6)alkyl, (C3-C8)cycloalkyl, (C6-C10)aryl and heterocyclyl;
• wherein R5, R6, R7 and t are as defined above;
• (C3-C8)cycloalkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of oxo, halogen, hydroxy, cyano, nitro, —NR5R6, —C(O)R5, —C(O)NR5R6, —S(O)tR7, (C1-C6)alkyl, halo(C1-C6)alkyl and —O(C 1-C6)alkyl;
• wherein R5, R6, R7 and t are as defined above;
• (C5-C8)cycloalkenyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, nitro, —NR5R6, —C(O)R5, —C(O)NR5R6, —S(O)tR7, (C1-C6)alkyl, halo(C1-C6)alkyl and —O(C1-C6)alkyl;
• wherein R5, R6, R7 and t are as defined above;
• (C6-C10)aryl is unsubstituted or substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, nitro,
• —C(O)R5, —C(O)OR5, —S(O)tR7, —NR5R6, (C1-C6)alkyl, halo(C1-C6)alkyl, —O(C1-C6)alkyl, halo(C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, —O(C6-C10)aryl, heterocyclyl and heteroaryl, wherein R5, R6, R7 and t are as defined above;
• heterocyclyl is a 3- to 11-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, nitro, —C(O)R5, —C(O)OR5, —S(O)tR7, —NR5R6, (C1-C6)alkyl, halo(C1-C6)alkyl, —O(C1-C6)alkyl, halo(C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, heterocyclyl and heteroaryl;
• wherein R5, R6, R7 and t are as defined above;
• heteroaryl is a 5- to 10-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, nitro, —C(O)R5, —C(O)OR5, —S(O)tR7, —NR5R6, (C1-C6)alkyl, halo(C1-C6)alkyl, —O(C1-C6)alkyl, halo(C1-C6)alkoxy, (C3-C8)cycloalkyl, (C6-C10)aryl, heterocyclyl and heteroaryl;
• wherein R5, R6, R7 and t are as defined above;
• halogen is chlorine, bromine, iodine or fluorine;
• or an isotopic form, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof.